{ "id": "epyp7n80j3", "slug": "mild-hyperthermia", "title": "Mild hyperthermia", "updated": "2026-10-15", "topic_path": [ { "id": "life", "label": "Life and health", "api_url": "https://www.edgepedia.org/api/v1/topics/life" }, { "id": "life.health", "label": "Human health and medicine", "api_url": "https://www.edgepedia.org/api/v1/topics/life.health" }, { "id": "life.health.clinical", "label": "Clinical assessment and procedures", "api_url": "https://www.edgepedia.org/api/v1/topics/life.health.clinical" }, { "id": "life.health.clinical.alpha-m-to-w", "label": "Titles M to W", "api_url": "https://www.edgepedia.org/api/v1/topics/life.health.clinical.alpha-m-to-w" } ], "geo": [ { "id": "geo.nongeo.t1946.life.health.clinical.alpha-m-to-w", "label": "Non-geographic · 1946 to 2000: Titles M to W", "api_url": "https://www.edgepedia.org/api/v1/geo/geo.nongeo.t1946.life.health.clinical.alpha-m-to-w", "path": [ { "id": "geo.nongeo", "label": "Non-geographic", "api_url": "https://www.edgepedia.org/api/v1/geo/geo.nongeo" }, { "id": "geo.nongeo.t1946", "label": "Non-geographic · 1946 to 2000", "api_url": "https://www.edgepedia.org/api/v1/geo/geo.nongeo.t1946" }, { "id": "geo.nongeo.t1946.life", "label": "Life and health", "api_url": "https://www.edgepedia.org/api/v1/geo/geo.nongeo.t1946.life" }, { "id": "geo.nongeo.t1946.life.health", "label": "Human health and medicine", "api_url": "https://www.edgepedia.org/api/v1/geo/geo.nongeo.t1946.life.health" }, { "id": "geo.nongeo.t1946.life.health.clinical", "label": "Clinical assessment and procedures", "api_url": "https://www.edgepedia.org/api/v1/geo/geo.nongeo.t1946.life.health.clinical" }, { "id": "geo.nongeo.t1946.life.health.clinical.alpha-m-to-w", "label": "Titles M to W", "api_url": "https://www.edgepedia.org/api/v1/geo/geo.nongeo.t1946.life.health.clinical.alpha-m-to-w" } ] } ], "excerpt": "Mild hyperthermia is a cancer treatment that heats tumors to about 39–45 °C, sensitizing cells to radiotherapy and chemotherapy, unlike ablation, which destroys tissue above 50 °C.", "snippet": "Mild hyperthermia is a cancer treatment that heats tumors to about 39–45 °C, sensitizing cells to radiotherapy and chemotherapy, unlike ablation, which destroys tissue above 50 °C.", "node": "life.health.clinical.alpha-m-to-w", "markdown": "# Mild hyperthermia\n\nMild hyperthermia is a cancer treatment that heats tumor tissue to about 39–45 °C, warm enough to sensitize cells to radiotherapy and chemotherapy but far below the temperatures used for thermal ablation.[1](https://pmc.ncbi.nlm.nih.gov/articles/PMC7781160/) Many reviews use a narrower convention of 39–43 °C,[2](https://mdpi-res.com/d_attachment/cancers/cancers-13-01243/article_deploy/cancers-13-01243.pdf?version=1615532513) and some sources extend mild or moderate hyperthermia to 45 °C,[1](https://pmc.ncbi.nlm.nih.gov/articles/PMC7781160/) consistent with the [National Cancer Institute](https://www.edgepedia.org/national-cancer-institute)'s description of heating tissue \"to as high as 113 °F\" (about 45 °C).[3](https://www.cancer.gov/about-cancer/treatment/types/hyperthermia) [Hyperthermia](https://www.edgepedia.org/hyperthermia) is used as an adjunct to chemotherapy, immunotherapy, or radiotherapy rather than instead of them.[4](https://link.springer.com/article/10.1186/s13014-025-02741-5)\n\n| Key fact | Detail |\n|---|---|\n| Temperature range | About 39–45 °C; 39–43 °C is the convention used in many reviews[1](https://pmc.ncbi.nlm.nih.gov/articles/PMC7781160/) • [2](https://mdpi-res.com/d_attachment/cancers/cancers-13-01243/article_deploy/cancers-13-01243.pdf?version=1615532513) • [4](https://link.springer.com/article/10.1186/s13014-025-02741-5) |\n| Distinction from ablation | Ablation destroys tissue directly at temperatures beyond 50 °C; mild hyperthermia sensitizes cells instead[1](https://pmc.ncbi.nlm.nih.gov/articles/PMC7781160/) |\n| Standard session | About 40–43 °C for roughly 60 min, usually after radiotherapy, once weekly[5](https://www.tandfonline.com/doi/full/10.1080/02656736.2016.1195924) |\n| Landmark pelvic trial | Complete response 39% with radiotherapy alone vs 55% with radiotherapy plus hyperthermia in 358 patients[6](https://www.ncbi.nlm.nih.gov/books/NBK13291/) |\n| Cervical cancer subgroup | Complete response 57% vs 83%; 3-year survival 27% vs 51%[7](https://www.tandfonline.com/doi/abs/10.1080/02656730110091919) |\n| Sarcoma trial | EORTC 62961-ESHO 95: 2-year LPFS hazard ratio 0.58; median overall survival 15.4 vs 6.2 years[8](https://oncotherm.com/wp-content/uploads/2024/06/ChiaBSH-et-al_2023_Review-of-the-current-clinical-evidence-for-loco-regional-moderate-hyperthermia.pdf) |\n| Thermal dose metrics | CEM43 and TRISE quantify combined temperature and duration; T90 summarizes the temperature exceeded by 90% of measured points[9](https://www.ejcancer.com/article/S0959-8049%2809%2900192-0/abstract) |\n\n## How it works\n\n**DNA repair inhibition.** Heat at temperatures exceeding about 41 °C damages proteins in DNA-damage response pathways, including non-homologous end joining, homologous recombination, and back-up non-homologous end joining, the pathways that repair the double-strand breaks caused by radiation.[10](https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2024.1428065/full) In the 40–42 °C range, cells are sensitized rather than killed directly.[11](https://mdpi-res.com/d_attachment/cancers/cancers-14-01701/article_deploy/cancers-14-01701-v3.pdf?version=1648707767) Direct thermal toxicity through denaturation of structural proteins begins above about 42.5 °C.[12](https://ccnm.edu/sites/default/files/2024-05/Hyperthermia-professional-resource-Dec2023.pdf)\n\n**Perfusion and oxygenation.** Heating up to about 42 °C induces transient vasodilation of abnormal tumor vessels and increased vascular permeability.[10](https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2024.1428065/full) Temperatures of 39–43 °C held for 30–60 min increase tumor perfusion for the following 4–8 h, normalizing oxygen, nutrient, and pH levels.[2](https://mdpi-res.com/d_attachment/cancers/cancers-13-01243/article_deploy/cancers-13-01243.pdf?version=1615532513) Reoxygenation persists for 24–48 h, and it correlates with outcome: pathologic complete response doubled in human soft tissue sarcomas, and responding locally advanced breast cancers showed a 14 mmHg increase in tumor \\( p_{\\mathrm{O_2}} \\) versus a 9 mmHg decrease in non-responders.[11](https://mdpi-res.com/d_attachment/cancers/cancers-14-01701/article_deploy/cancers-14-01701-v3.pdf?version=1648707767) Above about 42 °C the effect reverses, with heat damaging tumor vasculature and worsening hypoxia.[10](https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2024.1428065/full)\n\n**Thermal dose.** Because outcome depends on both temperature and time, dose is expressed as CEM43, the cumulative equivalent minutes at 43 °C, and as T90, the temperature exceeded by 90% of measured points.[6](https://www.ncbi.nlm.nih.gov/books/NBK13291/) In 420 cervical cancer patients treated with radiotherapy plus hyperthermia, both CEM43T90 and the alternative TRISE parameter correlated significantly and independently with tumor control and survival, with TRISE the more influential.[9](https://www.ejcancer.com/article/S0959-8049%2809%2900192-0/abstract)\n\n## How it is done\n\nDelivery is grouped into local, regional, and whole-body approaches.[3](https://www.cancer.gov/about-cancer/treatment/types/hyperthermia) For deep pelvic tumors, the BSD-2000 applies radiofrequency energy at 75–120 MHz through an array of antennae surrounding the body, using constructive and destructive interference to focus energy on the tumor.[13](https://www.accessdata.fda.gov/cdrh_docs/pdf9/H090002b.pdf) Capacitive devices operate at 8–13 MHz, and radiative phased arrays at 70–150 MHz.[14](https://www.ovid.com/journals/ijgync/fulltext/10.1136/ijgc-2021-002473~the-role-of-hyperthermia-in-the-treatment-of-locally) Microwaves and radiofrequency waves generally penetrate 3–5 cm, and radiative heating uses a water bolus for electromagnetic coupling.[4](https://link.springer.com/article/10.1186/s13014-025-02741-5) • [15](https://pmc.ncbi.nlm.nih.gov/articles/PMC7570290.pdf) Superficial and interstitial heating commonly uses the BSD-500 system, a 915 MHz modified dipole antenna array with up to 24 antennas and 8 thermistor channels.[1](https://pmc.ncbi.nlm.nih.gov/articles/PMC7781160/) Interstitial techniques also include 375 kHz needle electrodes, laser fiber optics, and magnetic fluid hyperthermia with nanoparticles.[16](https://www.ncbi.nlm.nih.gov/books/NBK6347/) Whole-body hyperthermia uses a thermal chamber or hot water blankets to raise body temperature to 107–108 °F for short periods.[3](https://www.cancer.gov/about-cancer/treatment/types/hyperthermia)\n\nTemperature control remains largely invasive: probes (thermistors, fiber optics, thermocouples) are placed in the bladder, vagina or cervix, and rectum, oriented about 90° to the electromagnetic field.[14](https://www.ovid.com/journals/ijgync/fulltext/10.1136/ijgc-2021-002473~the-role-of-hyperthermia-in-the-treatment-of-locally) • [4](https://link.springer.com/article/10.1186/s13014-025-02741-5) MRI-based non-invasive thermometry is under development but not standardized.[4](https://link.springer.com/article/10.1186/s13014-025-02741-5) A standard adequate treatment is approximately 42 °C for 60 minutes,[14](https://www.ovid.com/journals/ijgync/fulltext/10.1136/ijgc-2021-002473~the-role-of-hyperthermia-in-the-treatment-of-locally) typically given once weekly after radiotherapy.[5](https://www.tandfonline.com/doi/full/10.1080/02656736.2016.1195924) Because the heat stress response makes cells transiently thermotolerant, sessions are scheduled at least three days apart.[2](https://mdpi-res.com/d_attachment/cancers/cancers-13-01243/article_deploy/cancers-13-01243.pdf?version=1615532513)\n\n## Origin\n\nEarly published accounts describe local heating of cervical tumors with an intravaginal metal coil carrying water heated to 42–44 °C for 48 hours, combined with regional hot baths, and separate reports of whole-body heating with radiant energy from incandescent bulbs, maintaining 41–41.5 °C for 5–21 hours.[17](https://onlinelibrary.wiley.com/doi/10.1155/2013/428027) • [18](https://repub.eur.nl/pub/51173/870408_ZEE-Jacoba-van-der.pdf) The modern revival is traced to work on hyperthermic regional limb perfusion at 41.5–43.5 °C, which produced complete tumor disappearance in 10 of 22 patients.[18](https://repub.eur.nl/pub/51173/870408_ZEE-Jacoba-van-der.pdf) The pivotal modern trial was the Dutch Deep Hyperthermia Trial, reported by van der Zee and colleagues in [The Lancet](https://www.edgepedia.org/the-lancet) in 2000, which randomized patients with locally advanced pelvic tumors to radiotherapy alone or radiotherapy plus once-weekly hyperthermia.[19](https://doi.org/10.1016/s0140-6736%2800%2902059-6)\n\n## Variants\n\n**Modulated electro-hyperthermia (mEHT)**, delivered by the EHY-2000+ device at 13.56 MHz, differs from conventional heating by targeting the extracellular matrix and malignant cell membranes rather than heating the tumor homogeneously; its dose is measured by energy deposited in the tumor rather than achieved temperature.[20](https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2019.01012/full) • [15](https://pmc.ncbi.nlm.nih.gov/articles/PMC7570290.pdf) **Nanoparticle-mediated heating** is moving into the clinic: an iron oxide magnetic nanoparticle agent activated by time-varying magnetic fields has entered an investigational study with chemotherapy for locally advanced pancreatic cancer at Vall d'Hebron [University Hospital](https://www.edgepedia.org/university-hospital),[21](https://pubs.acs.org/aamick/article/17/2/2924/3630679/Preclinical-Development-of-Magnetic-Nanoparticles) and gold nanoparticles have been tested in a clinical pilot study of [photothermal ablation](https://www.edgepedia.org/photothermal-ablation) for localized prostate cancer.[10](https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2024.1428065/full) **Closed-loop whole-body hyperthermia** is exemplified by the MATTERS first-in-human trial, which treated 12 patients, mostly with metastatic pancreatic cancer, at 41.50 °C for 2, 4, and 6 hours using the TempoCure device; the treatment was safe and tolerable alone or with chemotherapy.[22](https://aacrjournals.org/cancerrescommun/article/6/2/273/774185/The-MATTERS-Trial-Safety-and-Tolerability-of-Whole)\n\n## Applications\n\n**Locally advanced pelvic tumors.** The Dutch trial randomized 358 patients with rectal, bladder, or cervical carcinoma: complete response was 39% with radiotherapy alone versus 55% with added hyperthermia (\\( p < 0.001 \\)).[6](https://www.ncbi.nlm.nih.gov/books/NBK13291/) In the 114-patient cervical cancer subgroup, complete response rose from 57% to 83% (\\( p = 0.003 \\)), 3-year overall survival from 27% to 51% (\\( p = 0.009 \\)), and the addition was cost-effective at a maximum discounted cost per life-year gained of about Euro 4000.[7](https://www.tandfonline.com/doi/abs/10.1080/02656730110091919) A meta-analysis of six randomized trials found hyperthermia plus radiotherapy improved complete response by 22% and locoregional control by 23% (both \\( p < 0.001 \\)), with a number needed to treat of 4.5 for complete response.[5](https://www.tandfonline.com/doi/full/10.1080/02656736.2016.1195924) When chemotherapy is added, a network meta-analysis of 13 studies ranked thermochemoradiotherapy best for complete response (SUCRA 0.952), ahead of chemoradiotherapy alone (0.317).[5](https://www.tandfonline.com/doi/full/10.1080/02656736.2016.1195924)\n\n**Other sites.** In the EORTC 62961-ESHO 95 sarcoma trial (341 patients, BSD-2000), extremity sarcoma response rates were 28.8% versus 12.7% (\\( p = 0.002 \\)), 2-year LPFS hazard ratio 0.58, and median overall survival after more than 11 years was 15.4 versus 6.2 years (HR 0.73, \\( p = 0.04 \\)); this led to regional hyperthermia's inclusion in NCCN and ESMO guidelines for soft tissue sarcoma.[8](https://oncotherm.com/wp-content/uploads/2024/06/ChiaBSH-et-al_2023_Review-of-the-current-clinical-evidence-for-loco-regional-moderate-hyperthermia.pdf) A nasopharyngeal carcinoma trial adding microwave hyperthermia to chemoradiotherapy improved 5-year local control (96.1% vs 76.9%), disease-free survival (51.3% vs 20.5%), and overall survival (68.4% vs 50.0%), each \\( p = 0.001 \\).[8](https://oncotherm.com/wp-content/uploads/2024/06/ChiaBSH-et-al_2023_Review-of-the-current-clinical-evidence-for-loco-regional-moderate-hyperthermia.pdf) Hyperthermia has been included in the NCCN guidelines for recurrent breast cancer since 2013.[15](https://pmc.ncbi.nlm.nih.gov/articles/PMC7570290.pdf) The National Cancer Institute notes that hyperthermia is not widely available and that whether it helps people live longer remains unclear.[3](https://www.cancer.gov/about-cancer/treatment/types/hyperthermia)\n\n## Limitations and alternatives\n\n**Heating quality.** Capacitive radiofrequency heating becomes less effective as fat-layer thickness increases, making deep-seated tumors hard to heat uniformly.[1](https://pmc.ncbi.nlm.nih.gov/articles/PMC7781160/) Non-invasive thermometry is harder for hyperthermia than for ablation because the required temperature resolution is much finer (a 1–6 °C rise versus 10–40 °C for ablation); proton resonance frequency shift MR thermometry reaches about 1 °C accuracy only under favorable low-flow conditions.[1](https://pmc.ncbi.nlm.nih.gov/articles/PMC7781160/) Heterogeneous practices and poor quality assurance have hindered wider adoption.[8](https://oncotherm.com/wp-content/uploads/2024/06/ChiaBSH-et-al_2023_Review-of-the-current-clinical-evidence-for-loco-regional-moderate-hyperthermia.pdf)\n\n**Toxicity.** Reported adverse effects of deep hyperthermia include pain, blistering, burns, ulceration, fat or muscle necrosis, and thermal stress.[13](https://www.accessdata.fda.gov/cdrh_docs/pdf9/H090002b.pdf) For chest wall treatment, first- or second-degree burns occur in about 5% of patients and third-degree burns in less than 1%.[6](https://www.ncbi.nlm.nih.gov/books/NBK13291/) Neural tissue is more heat-sensitive than most normal tissue: temperatures above 42 °C for 1 hour caused irreversible damage in animal models, while most normal tissues tolerate up to 44 °C for 1 hour.[23](https://www.degruyterbrill.com/document/doi/10.1515/oncologie-2024-0674/html) Benefit also depends on tumor size; in the RTOG 81-04 trial of superficial tumors, complete response was 32% versus 30%, with benefit confined to tumors smaller than 3 cm.[6](https://www.ncbi.nlm.nih.gov/books/NBK13291/)\n\n**Comparisons.** Against chemoradiotherapy alone, the network meta-analysis above favors adding hyperthermia for complete response.[5](https://www.tandfonline.com/doi/full/10.1080/02656736.2016.1195924) MR-guided high-intensity focused ultrasound can induce stable mild hyperthermia to trigger drug release from thermosensitive liposomes in animal models, but a single electronically steered focus limits the stable heated volume to a few cubic centimeters, keeping the application experimental.[1](https://pmc.ncbi.nlm.nih.gov/articles/PMC7781160/) Published reviews differ on the definitional boundaries: the upper limit of mild hyperthermia is given as 43 °C in some reviews and 45 °C in others,[2](https://mdpi-res.com/d_attachment/cancers/cancers-13-01243/article_deploy/cancers-13-01243.pdf?version=1615532513) • [4](https://link.springer.com/article/10.1186/s13014-025-02741-5) and the ablation threshold is quoted as beyond 50 °C[1](https://pmc.ncbi.nlm.nih.gov/articles/PMC7781160/) or above 60 °C.[11](https://mdpi-res.com/d_attachment/cancers/cancers-14-01701/article_deploy/cancers-14-01701-v3.pdf?version=1648707767)\n\n## References\n\n1. [Heating technology for malignant tumors: a review](https://pmc.ncbi.nlm.nih.gov/articles/PMC7781160/)\n2. [Modulating the Heat Stress Response to Improve Hyperthermia-Based Anticancer Treatments (Cancers 2021)](https://mdpi-res.com/d_attachment/cancers/cancers-13-01243/article_deploy/cancers-13-01243.pdf?version=1615532513)\n3. [Hyperthermia to Treat Cancer, National Cancer Institute](https://www.cancer.gov/about-cancer/treatment/types/hyperthermia)\n4. [The role of hyperthermia in modern radiation treatment - state of art (Radiation Oncology, 2025)](https://link.springer.com/article/10.1186/s13014-025-02741-5)\n5. [Hyperthermia and radiotherapy with or without chemotherapy in locally advanced cervical cancer: a systematic review with conventional and network meta-analyses](https://www.tandfonline.com/doi/full/10.1080/02656736.2016.1195924)\n6. [Clinical Hyperthermia (Holland-Frei Cancer Medicine)](https://www.ncbi.nlm.nih.gov/books/NBK13291/)\n7. [The Dutch Deep Hyperthermia Trial: results in cervical cancer](https://www.tandfonline.com/doi/abs/10.1080/02656730110091919)\n8. [A Review of the Current Clinical Evidence for Loco-Regional Moderate Hyperthermia in the Adjunct Management of Cancers](https://oncotherm.com/wp-content/uploads/2024/06/ChiaBSH-et-al_2023_Review-of-the-current-clinical-evidence-for-loco-regional-moderate-hyperthermia.pdf)\n9. [abstract (ejcancer.com)](https://www.ejcancer.com/article/S0959-8049%2809%2900192-0/abstract)\n10. [Hyperthermia and radiotherapy: physiological basis for a synergistic effect (Frontiers in Oncology, 2024)](https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2024.1428065/full)\n11. [Accurate Three-Dimensional Thermal Dosimetry and Assessment of Physiologic Response Are Essential for Optimizing Thermoradiotherapy (Cancers, MDPI)](https://mdpi-res.com/d_attachment/cancers/cancers-14-01701/article_deploy/cancers-14-01701-v3.pdf?version=1648707767)\n12. [Locoregional Hyperthermia clinical monograph (CCNM, Dec 2023)](https://ccnm.edu/sites/default/files/2024-05/Hyperthermia-professional-resource-Dec2023.pdf)\n13. [BSD-2000 Hyperthermia System, FDA premarket notification (device documentation)](https://www.accessdata.fda.gov/cdrh_docs/pdf9/H090002b.pdf)\n14. [The role of hyperthermia in the treatment of locally advanced cervical cancer (Int J Gynecological Cancer)](https://www.ovid.com/journals/ijgync/fulltext/10.1136/ijgc-2021-002473~the-role-of-hyperthermia-in-the-treatment-of-locally)\n15. [A Narrative Review of Regional Hyperthermia: Updates From 2010 up to 2019](https://pmc.ncbi.nlm.nih.gov/articles/PMC7570290.pdf)\n16. [Locoregional Hyperthermia, Madame Curie Bioscience Database (NCBI Bookshelf)](https://www.ncbi.nlm.nih.gov/books/NBK6347/)\n17. [The History of Hyperthermia Rise and Decline](https://onlinelibrary.wiley.com/doi/10.1155/2013/428027)\n18. [Hyperthermia in cancer therapy: the Rotterdam experience (van der Zee thesis)](https://repub.eur.nl/pub/51173/870408_ZEE-Jacoba-van-der.pdf)\n19. [Comparison of radiotherapy alone with radiotherapy plus hyperthermia in locally advanced pelvic tumours: a prospective, randomised, multicentre trial (The Lancet, 2000)](https://doi.org/10.1016/s0140-6736%2800%2902059-6)\n20. [Review of the Clinical Evidences of Modulated Electro-Hyperthermia (mEHT) Method (Frontiers in Oncology, 2019)](https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2019.01012/full)\n21. [Preclinical Development of Magnetic Nanoparticles for Hyperthermia Treatment of Pancreatic Cancer (ACS Applied Materials & Interfaces, 2025)](https://pubs.acs.org/aamick/article/17/2/2924/3630679/Preclinical-Development-of-Magnetic-Nanoparticles)\n22. [The MATTERS Trial: Safety and Tolerability of Whole-Body Hyperthermia at 41.5°C with Chemotherapy in Metastatic Cancer (Cancer Research Communications, 2026)](https://aacrjournals.org/cancerrescommun/article/6/2/273/774185/The-MATTERS-Trial-Safety-and-Tolerability-of-Whole)\n23. [Efficacy of mild hyperthermia in cancer therapy: balancing efficacy and safety (Oncologie, 2024/2025)](https://www.degruyterbrill.com/document/doi/10.1515/oncologie-2024-0674/html)\n\n---\n*Topic: Encyclopedia › Life and health › Human health and medicine › Clinical assessment and procedures › Titles M to W*\n\n*Initially written Sep 29, 2026 · Edited: Oct 15, 2026*\n\n*Copyright 2026 EdgeChat AI, a subsidiary of Biostate AI.*\n\nLicense: Edgepedia Community License 1.0, https://www.edgepedia.org/edgepedia/license\n", "same_as": [], "url": "https://www.edgepedia.org/mild-hyperthermia", "markdown_url": "https://www.edgepedia.org/mild-hyperthermia.md", "license": { "name": "Edgepedia Community License 1.0", "url": "https://www.edgepedia.org/edgepedia/license", "summary": "Free with credit, commercial use included. AI training is open to everyone. For other uses, organizations over USD 100M in revenue or 100M monthly users license separately.", "spdx": "LicenseRef-Edgepedia-Community-1.0" }, "credit": "\"Mild hyperthermia\", Edgepedia (EdgeChat), https://www.edgepedia.org/mild-hyperthermia. Edgepedia Community License 1.0.", "credit_md": "\"[Mild hyperthermia](https://www.edgepedia.org/mild-hyperthermia)\", Edgepedia (EdgeChat), [https://www.edgepedia.org/mild-hyperthermia](https://www.edgepedia.org/mild-hyperthermia). [Edgepedia Community License 1.0](https://www.edgepedia.org/edgepedia/license).", "credit_html": "\"Mild hyperthermia\", Edgepedia (EdgeChat), https://www.edgepedia.org/mild-hyperthermia. Edgepedia Community License 1.0.", "speakable": "Mild hyperthermia is a cancer treatment that heats tumors to about 39–45 °C, sensitizing cells to radiotherapy and chemotherapy, unlike ablation, which destroys tissue above 50 °C." }